Skip To Main Content
Murua Escobar on Muck Rack

Murua Escobar

As seen in: Frontiers, Biomed Central (BMC)
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Murua

Contact Murua, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Proteomic analysis of extracellular vesicles derived from canine mammary tumour cell lines identifies protein signatures specific for disease state - BMC Veterinary Research

|
By von Bergen, Murua Escobar, Freie Universität Berlin
| Biomed Central (BMC)
The following canine mammary cell lines were used: one non-neoplastic cell line (MTH53A, used as a healthy control), one simple adenoma cell line (ZMTH3), one simple carcinoma cell line (MTH52C) and two complex carcinoma cell lines (1305, DT1406TB).
Open in Who Shared Issue with article?

Frontiers | The TiHoCL panel for canine lymphoma: a feasibility study integrating functional genomics and network biology approaches for comparative oncology targeted NGS panel design

|
By Jillian M. Richmond, Diana Giannuzzi, Murua Escobar, Vittoria Castiglioni
| Frontiers
1 Introduction Driven by plummeting costs, next-generation sequencing (NGS) has revolutionized biomedical research, playing an instrumental role in advancing our understanding of the molecular basis of various diseases (1). NGS has numerous applications, ranging from whole-genome (re)sequencing to targeted sequencing for variant identification or confirmation.
Open in Who Shared Issue with article?

Tyrosine kinase inhibitors and molecularly driven therapeutic approaches for canine lymphoma: a systematic review and meta-analysis

|
By Murua Escobar
| Frontiers
Abstract Background: Canine lymphoma (cL), the second most common canine cancer after mammary carcinoma, presents therapeutic challenges due to limitations of conventional regimens, necessitating novel therapeutic approaches. Tyrosine kinase inhibitors (TKIs), which have demonstrated efficacy in human non-Hodgkin lymphoma (NHL), are increasingly being investigated as targeted therapies for cL, which also serves as a valuable translational model for NHL research.
Open in Who Shared Issue with article?
See all 3 articles